Details

Autor(en) / Beteiligte

• Crosignani, Andrea
• Battezzati, Pier Maria
• Cestari, Cristina
• Stabilini, Roberto
• Conte, Dario
• Zappalà, Francesco
• Floreani, Annarosa
• Montalto, Giuseppe
• Soresi, Maurizio
• Notarbartolo, Alberto
• Buscarini, Elisabetta
• Buscarini, Luigi
• Buongiorno, Giampiero
• Manghisi, Onofrio Giuseppe
• Podda, Mauro

Titel

Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study

Ist Teil von

• Hepatology research, 1998-12, Vol.13 (1), p.10-19

Ort / Verlag

Shannon: Elsevier Ireland Ltd

Erscheinungsjahr

1998

Beschreibungen/Notizen

• Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls ( P<0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg ( P<0.05). A progressive improvement of alanine aminotransferase (ALT) with time ( P<0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.